Menu Search
Equities

Aelis Farma SA

AELIS:PAR

Aelis Farma SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)3.06
  • Today's Change-0.02 / -0.65%
  • Shares traded106.00
  • 1 Year change-77.08%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 15:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in EURView more

In 2023, cash reserves at Aelis Farma SA fell by 14.19m. Cash Flow from Investing was negative at 88.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 12.96m for operations while cash used for financing totalled 968.00k.
Cash flow per share-0.5138
Price/Cash flow per share--
Book value per share0.75
Tangible book value per share0.7357
More ▼

Balance sheet in EURView more

Aelis Farma SA appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.48% of the market capitalization can be attributed to its 20.23m and debt could be paid in full if management chose.
Current ratio2.97
Quick ratio2.97
Total debt/total equity0.383
Total debt/total capital0.277
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.